Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | +2.94% | +0.57% | -25.53% |
Financials (USD)
Sales 2024 * | 184M | Sales 2025 * | 219M | Capitalization | 252M |
---|---|---|---|---|---|
Net income 2024 * | -55M | Net income 2025 * | -27M | EV / Sales 2024 * | 1.37 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.15 x |
P/E ratio 2024 * |
-4.42
x | P/E ratio 2025 * |
-9.27
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.26% |
Latest transcript on Xeris Biopharma Holdings, Inc.
1 day | +2.94% | ||
1 week | +0.57% | ||
Current month | -20.81% | ||
1 month | -14.63% | ||
3 months | -29.72% | ||
6 months | +5.42% | ||
Current year | -25.53% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 04-12-31 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 21-10-04 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +6.26% | - | |
0.00% | 147 M€ | +4.88% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.75 | +2.94% | 857 666 |
24-04-25 | 1.7 | -3.41% | 894,039 |
24-04-24 | 1.76 | -1.12% | 712,941 |
24-04-23 | 1.78 | 0.00% | 1,345,307 |
24-04-22 | 1.78 | +2.30% | 1,319,079 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.53% | 252M | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |
- Stock Market
- Equities
- XERS Stock